ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts
Laxminarasimha Donthireddy, Prashanthi Vonteddu, Tushar Murthy, Taekyoung Kwak, Rukiye-Nazan Eraslan, Joseph R. Podojil, Adam Elhofy, Michael T. Boyne, John Puisis, Filippo Veglia, Surya Satyanarayana Singh, Farokh Dotiwala, Luis J. Montaner, Dmitry I. Gabrilovich · Journal of Cancer · 2022
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2022
Abstract
In this study, we evaluated the ability of negatively charged bio-degradable nanoparticles, ONP- 302, to inhibit tumor growth. Therapeutic treatment with ONP-302 in vivo resulted in a marked delay in tumor growth in three different syngeneic tumor models in immunocompetent mice. ONP- 302 efficacy persisted with depletion of CD8+ T cells in immunocompetent mice and also was effective in immune deficient mice. Examination of ONP-302 effects on components of the tumor microenvironment (TME) were explored.
ONP-302 treatment caused a gene expression shift in TAMs toward the pro-inflammatory M1 type and substantially inhibited the expression of genes associated with the pro-tumorigenic function of CAFs. ONP-302 also induced apoptosis in CAFs in the TME. Together, these data support further development of ONP-302 as a novel first-in- class anti-cancer therapeutic that can be used as a single-agent as well as in combination therapies for the treatment of solid tumors due to its ability to modulate the TME.
Open the resolved locator · 10.7150/jca.69338
Metadata licence: OpenAlex metadata (CC0)